Anti-Human CD20 (Rituximab) [Clone 10F381] – APC
Anti-Human CD20 (Rituximab) [Clone 10F381] – APC
Product No.: LT903
Product No.LT903 Clone 10F381 Target CD20 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1 Isotype Human IgG1κ Applications FC |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Rhesus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphoblastoid cell line SB. Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) RRIDAB_2894033 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only. Background CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects. Antigen Distribution CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Using Research-Grade Rituximab Biosimilars in PK Bridging ELISARituximab biosimilars, which are structurally and functionally similar to the reference medicinal product Rituximab (Rituxan or Mabthera), play a critical role as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays. These assays are designed to measure the concentration of Rituximab in serum samples, providing valuable data for pharmacokinetic studies. Calibration and Principle
Role in PK Bridging Studies
In summary, research-grade Rituximab biosimilars are used as calibration standards in PK bridging ELISA assays to ensure accurate measurement of Rituximab concentrations in serum samples. This accuracy is crucial for pharmacokinetic studies, which are essential for establishing the bioequivalence of biosimilars to their reference drugs. Standard flow cytometry protocols involving a conjugated Rituximab biosimilar (e.g., PE or APC-labeled) are used to directly assess CD20 expression and the binding capacity of therapeutic anti-CD20 antibodies on B cells, in research and quality control settings. The established procedural workflow typically includes:
Key protocol notes and considerations:
Typical usage scenarios include:
The protocols may differ slightly between research, clinical, and manufacturing environments, but the outlined approach remains consistent. Biopharma companies use a comprehensive set of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to its originator (reference) drug. These assays target both structural attributes (such as amino acid sequence and folding) and functional activities (such as target binding and biological efficacy), with results forming the core evidence required by regulatory bodies for biosimilar approval. Key Analytical Assays and Their Purposes
Where the Leinco Biosimilar Is UsedLeinco is known as a supplier of research-grade biosimilar antibodies and related reagents. In structural and functional similarity studies, Leinco biosimilar proteins may be used as:
However, for regulatory approval of a clinical biosimilar, direct comparison must ultimately use the FDA- or EMA-licensed originator product, not a commercial research biosimilar. Leinco’s biosimilars are mainly intended for research purposes, method development, or as secondary standards, rather than as the principal comparator in regulatory filings. Summary Table of Analytical Assays for Biosimilarity
This comprehensive analytic and functional testing provides the totality of evidence required to demonstrate biosimilarity, with close head-to-head comparison to the reference product at every stage. References & Citations1. Mato, A. et al. (2018) Oncologist. 23(3):288-296. 2. Richards, K. et al. (2018) Front Oncol. 8: 163. Technical ProtocolsCertificate of Analysis |
Formats Available
